PMC:7243768 / 36274-37494 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T313","span":{"begin":306,"end":311},"obj":"Body_part"},{"id":"T314","span":{"begin":598,"end":605},"obj":"Body_part"}],"attributes":[{"id":"A313","pred":"fma_id","subj":"T313","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A314","pred":"fma_id","subj":"T314","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"6.4 SARS-CoV-2 – diabetes mellitus\nPatients with diabetes mellitus exhibit high levels of ACE2, and treatment with the inhibitors of ACE and ARBs augments the expression of ACE2. Diabetes condition may lead to the suspicion that the excessive expression of ACE2 aids the entry of SARS-CoV-2 into the host cells resulting in COVID-19. Since diabetes mellitus and hypertension conditions are treated, ACE2 increasing drugs are having a severe risk of COVID-19 [10].\nSimultaneously, the elevated expression of ACE2 ensures the entry of the SARS-CoV-2, attaching to the ACE2 enzyme with the help of S protein present on its envelope's surface. There forth, it became controversial whether COVID-19 affected patients who are predisposed with diabetes mellitus should be resumed with their treatment with ACEi and ARBs or not. Also, if the medication is abruptly ceased, there are chances that the patient may die due to hypertension instead of COVID-19. For this reason, it has been suggested that there is no need to stop the medication of a diabetic patient even though if he is affected by COVID-19 because there is no scientific evidence available conducted on human subjects regarding whether to use ACEi and ARBs [10]."}

LitCovid-PD-MONDO

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T498","span":{"begin":306,"end":311},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T499","span":{"begin":433,"end":434},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T500","span":{"begin":970,"end":973},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T501","span":{"begin":1037,"end":1038},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T502","span":{"begin":1161,"end":1166},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"}],"text":"6.4 SARS-CoV-2 – diabetes mellitus\nPatients with diabetes mellitus exhibit high levels of ACE2, and treatment with the inhibitors of ACE and ARBs augments the expression of ACE2. Diabetes condition may lead to the suspicion that the excessive expression of ACE2 aids the entry of SARS-CoV-2 into the host cells resulting in COVID-19. Since diabetes mellitus and hypertension conditions are treated, ACE2 increasing drugs are having a severe risk of COVID-19 [10].\nSimultaneously, the elevated expression of ACE2 ensures the entry of the SARS-CoV-2, attaching to the ACE2 enzyme with the help of S protein present on its envelope's surface. There forth, it became controversial whether COVID-19 affected patients who are predisposed with diabetes mellitus should be resumed with their treatment with ACEi and ARBs or not. Also, if the medication is abruptly ceased, there are chances that the patient may die due to hypertension instead of COVID-19. For this reason, it has been suggested that there is no need to stop the medication of a diabetic patient even though if he is affected by COVID-19 because there is no scientific evidence available conducted on human subjects regarding whether to use ACEi and ARBs [10]."}

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T194","span":{"begin":120,"end":130},"obj":"Chemical"},{"id":"T195","span":{"begin":416,"end":421},"obj":"Chemical"},{"id":"T196","span":{"begin":598,"end":605},"obj":"Chemical"},{"id":"T197","span":{"begin":800,"end":804},"obj":"Chemical"},{"id":"T198","span":{"begin":1201,"end":1205},"obj":"Chemical"}],"attributes":[{"id":"A194","pred":"chebi_id","subj":"T194","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A195","pred":"chebi_id","subj":"T195","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A196","pred":"chebi_id","subj":"T196","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A197","pred":"chebi_id","subj":"T197","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A198","pred":"chebi_id","subj":"T198","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"}],"text":"6.4 SARS-CoV-2 – diabetes mellitus\nPatients with diabetes mellitus exhibit high levels of ACE2, and treatment with the inhibitors of ACE and ARBs augments the expression of ACE2. Diabetes condition may lead to the suspicion that the excessive expression of ACE2 aids the entry of SARS-CoV-2 into the host cells resulting in COVID-19. Since diabetes mellitus and hypertension conditions are treated, ACE2 increasing drugs are having a severe risk of COVID-19 [10].\nSimultaneously, the elevated expression of ACE2 ensures the entry of the SARS-CoV-2, attaching to the ACE2 enzyme with the help of S protein present on its envelope's surface. There forth, it became controversial whether COVID-19 affected patients who are predisposed with diabetes mellitus should be resumed with their treatment with ACEi and ARBs or not. Also, if the medication is abruptly ceased, there are chances that the patient may die due to hypertension instead of COVID-19. For this reason, it has been suggested that there is no need to stop the medication of a diabetic patient even though if he is affected by COVID-19 because there is no scientific evidence available conducted on human subjects regarding whether to use ACEi and ARBs [10]."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T244","span":{"begin":0,"end":35},"obj":"Sentence"},{"id":"T245","span":{"begin":36,"end":179},"obj":"Sentence"},{"id":"T246","span":{"begin":180,"end":334},"obj":"Sentence"},{"id":"T247","span":{"begin":335,"end":464},"obj":"Sentence"},{"id":"T248","span":{"begin":465,"end":640},"obj":"Sentence"},{"id":"T249","span":{"begin":641,"end":821},"obj":"Sentence"},{"id":"T250","span":{"begin":822,"end":949},"obj":"Sentence"},{"id":"T251","span":{"begin":950,"end":1220},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"6.4 SARS-CoV-2 – diabetes mellitus\nPatients with diabetes mellitus exhibit high levels of ACE2, and treatment with the inhibitors of ACE and ARBs augments the expression of ACE2. Diabetes condition may lead to the suspicion that the excessive expression of ACE2 aids the entry of SARS-CoV-2 into the host cells resulting in COVID-19. Since diabetes mellitus and hypertension conditions are treated, ACE2 increasing drugs are having a severe risk of COVID-19 [10].\nSimultaneously, the elevated expression of ACE2 ensures the entry of the SARS-CoV-2, attaching to the ACE2 enzyme with the help of S protein present on its envelope's surface. There forth, it became controversial whether COVID-19 affected patients who are predisposed with diabetes mellitus should be resumed with their treatment with ACEi and ARBs or not. Also, if the medication is abruptly ceased, there are chances that the patient may die due to hypertension instead of COVID-19. For this reason, it has been suggested that there is no need to stop the medication of a diabetic patient even though if he is affected by COVID-19 because there is no scientific evidence available conducted on human subjects regarding whether to use ACEi and ARBs [10]."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T183","span":{"begin":18,"end":35},"obj":"Phenotype"},{"id":"T184","span":{"begin":50,"end":67},"obj":"Phenotype"},{"id":"T185","span":{"begin":341,"end":358},"obj":"Phenotype"},{"id":"T186","span":{"begin":363,"end":375},"obj":"Phenotype"},{"id":"T187","span":{"begin":738,"end":755},"obj":"Phenotype"},{"id":"T188","span":{"begin":916,"end":928},"obj":"Phenotype"}],"attributes":[{"id":"A183","pred":"hp_id","subj":"T183","obj":"http://purl.obolibrary.org/obo/HP_0000819"},{"id":"A184","pred":"hp_id","subj":"T184","obj":"http://purl.obolibrary.org/obo/HP_0000819"},{"id":"A185","pred":"hp_id","subj":"T185","obj":"http://purl.obolibrary.org/obo/HP_0000819"},{"id":"A186","pred":"hp_id","subj":"T186","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A187","pred":"hp_id","subj":"T187","obj":"http://purl.obolibrary.org/obo/HP_0000819"},{"id":"A188","pred":"hp_id","subj":"T188","obj":"http://purl.obolibrary.org/obo/HP_0000822"}],"text":"6.4 SARS-CoV-2 – diabetes mellitus\nPatients with diabetes mellitus exhibit high levels of ACE2, and treatment with the inhibitors of ACE and ARBs augments the expression of ACE2. Diabetes condition may lead to the suspicion that the excessive expression of ACE2 aids the entry of SARS-CoV-2 into the host cells resulting in COVID-19. Since diabetes mellitus and hypertension conditions are treated, ACE2 increasing drugs are having a severe risk of COVID-19 [10].\nSimultaneously, the elevated expression of ACE2 ensures the entry of the SARS-CoV-2, attaching to the ACE2 enzyme with the help of S protein present on its envelope's surface. There forth, it became controversial whether COVID-19 affected patients who are predisposed with diabetes mellitus should be resumed with their treatment with ACEi and ARBs or not. Also, if the medication is abruptly ceased, there are chances that the patient may die due to hypertension instead of COVID-19. For this reason, it has been suggested that there is no need to stop the medication of a diabetic patient even though if he is affected by COVID-19 because there is no scientific evidence available conducted on human subjects regarding whether to use ACEi and ARBs [10]."}